Activities of wild-type and variant tissue-type plasminogen activators retained on vascular endothelial cells

Yuko Suzuki, Hideto Sano, Martyna Tomczyk, Tomasz Brzoska and Tetsumei Urano

Department of Medical Physiology, Hamamatsu University School of Medicine, Japan

Keywords
fibrinolysis; tissue-type plasminogen activator; vascular endothelial cells

Correspondence
Y. Suzuki, Department of Medical Physiology, Hamamatsu University School of Medicine, 1-20-1 Handa-yama, Higashi-ku, Hamamatsu 431-3192, Japan
Fax: +81 53 435 7020
Tel: +81 53 435 2249
E-mail: seigan@hama-med.ac.jp

(Received 13 February 2016, revised 6 March 2016, accepted 7 March 2016)
doi:10.1002/2211-5463.12057

We reported that tissue-type plasminogen activator (tPA) secreted from vascular endothelial cells (VECs) is retained on the cell surface and effectively evokes both plasminogen activation and fibrin clot dissolution (fibrinolysis) on VECs. Here, to evaluate possibly different behaviors of variants of tPA, we quantitatively assessed these two events separately using green fluorescent protein (GFP)-conjugated tPA in cultured human VECs. The amount of secreted wild-type tPA-GFP correlated well with both the activities of plasminogen activation ($r = 0.66$) and fibrinolysis ($r = -0.93$). A variant of tPA-GFP, with a lower affinity to the surface of VECs but higher affinity to fibrin, showed higher fibrinolysis and lower plasminogen activation activity compared to the wild-type.

Tissue-type plasminogen activator (tPA), secreted from vascular endothelial cells (VECs) triggers intravascular fibrinolysis by activating plasminogen to plasmin [1]. Using green fluorescent protein (GFP)-conjugated tPA (tPA-GFP) and total internal reflection fluorescence (TIRF) microscopy, we studied the unique exocytotic dynamics of tPA-GFP and observed that tPA-GFP was retained on the VEC surface in a heavy-chain-dependent manner after exocytosis [2]. Such a slow discharge of tPA was also reported in adrenal chromaffin cells [3,4], in which tPA showed lower diffusion mobility after the fusion of the granule membrane with the plasma membrane due to a slower fusion-pore expansion by tPA.

Unlike other members of the family of serine proteases, tPA is secreted as an active form [5], and thus its ‘retention’ on the solid surface is directly related to the facilitated plasmin generation [6], since its substrate of plasminogen also binds to the VEC surface. Our previous findings [6] showed that fluorescent-labeled plasminogen progressively accumulated on tPA-GFP-expressing VEC surface/pericellular areas in a manner that was tPA-GFP activity-dependent and plasmin activity-dependent. Our prior findings further demonstrated that the surface-retained tPA-GFP effectively initiated the dissolution of fibrin clots (fibrinolysis) that had formed over tPA-GFP-expressing cells.

The prerequisite function of the solid phase was demonstrated in both of the phenomena described in the previous paragraph as follows: First, these phenomena were strongly attenuated when a mutant tPA-GFP lacking a heavy chain, which is responsible for the retention on VECs as well as fibrin binding, was expressed. Second, the inhibition of plasminogen binding to either the cell surface or fibrin by a lysine analog completely abolished these phenomena. We also

Abbreviations
CLSM, confocal laser scanning microscopy; CLT, clot lysis time; GFP, green fluorescent protein; PAI-1, plasminogen activator inhibitor-1; plg-568, Alexa Fluor 568-labeled plasminogen; ROI, region of interest; RPG, rate of plasmin generation; RR, retained ratio; TIRF, total internal reflection fluorescence; tPA, tissue-type plasminogen activator; VECs, vascular endothelial cells.
demonstrated that plasminogen activator inhibitor-1 (PAI-1), the primary inhibitor of tPA, formed a complex with retained tPA and facilitated its dissociation from secretory granule membranes to the fluid phase, which resulted in the reduction of the amount and activity of tPA on VECs [2]. The retention of tPA and its modification by PAI-1 thus appears to be important factors in the regulation of PA activity on the VEC surface.

In this study, we aimed to quantify VEC-associated plasminogen activator activities by two distinct methods: a modified conventional chromogenic assay for the assessment of plasminogen activation, and a clot lysis assay for the assessment of fibrinolytic activities. A combination of these methods enabled us to define the distinct characteristics of both wild-type and variant tPA (tenecteplase: TNK [T103N, N117Q, K296A, H297A, R298A, R299A]-tPA), the latter of which is shown to be associated with better reperfusion and clinical improvement as a thrombolytic drug for patients with stroke compared to wild-type tPA (alteplase) [7] and with safe and feasible agents for minor stroke with intracranial occlusion [8].

**Methods**

**Cell culture and plasmids**

Vascular endothelial cells, that is, human umbilical vein endothelial cell-derived EA.hy926 cells—which were established to retain endothelial cell-specific functions including their fibrinolytic characteristics—were kindly provided by Dr C.J. Edgell of the University of North Carolina at Chapel Hill [9,10] and cultured as described [2]. Using tPA-GFP plasmid vector [2] as a template, we generated TNK-tPA-GFP and K-tPA (K296A, H297A) plasmids using the QuickChange II site-directed mutagenesis kit (Stratagene, La Jolla, CA, USA), repeating the reaction several times to achieve the substitutions. The primer information is shown in the Table 1.

**Analysis of tPA-GFP retention on cell surface**

Cells cultured on 35-mm glass-bottom dishes (Asahi Techno Glass, Tokyo, Japan) were transiently transfected with tPAS-GFP by lipofection using a commercially available transfection reagent (TransIT-LT1, MIR2300; Mirus, Madison, WI, USA). After overnight incubation, the cells were washed with HEPES-buffered solution (HBS; 140 mM NaCl, 5 mM KCl, 1 mM MgCl₂, 2.5 mM CaCl₂, 10 mM glucose, and 10 mM HEPES-NaOH, pH 7.3) and then set on the TIRF microscope stage. Details of the microscope system and method of image capture are explained below.

| Table 1. Sequences of primers for variants of tPA-GFP plasmid vector |
|---------------------------------------------------------------|
| Thr-to-Asn at amino acid position 103 (T103N)                 |
| Forward 5'-CAG CTA CAG GGG CAA CTG GAG CAC AGC G-3            |
| Reverse 5'-CGG CTG TCC AGT TGC CCC TGT AGC TG-3               |
| Asn-to-Gln at amino acid position 117 (N117Q)                 |
| Forward 5'-GTG CAC CAA CTG GCA GAG CAC GCG GTT GG-3           |
| Reverse 5'-CCG AGC CCG TGG TCT GCC AGT TGG TGC AC-3           |
| Lys, His-to-Ala, Ala at amino acid position 296–297 (K296A, H297A) |
| Forward 5'-GCT GCC ATC TTT GCC GCG GCG AGG AGG TCG CCC GG-3   |
| Reverse 5'-CGG GGC GAC CTC CTC GCC GCG GCA AAG ATG GCA GC-3  |
| Arg, Arg-to-Ala, Ala at amino acid position 298–299 (R298A, R299A) |
| Forward 5'-CCA TCT TTG CCG CGG CGG CGT CCG GAG AGG G-3        |
| Reverse 5'-GCG TCT CCG GCC GAC GCC GCC GCC GCC GCA GC-3       |

The retained ratio (RR) of tPA-GFP in individual secretory granules after secretion was determined by recording 3-min movies captured at 3.2 frames per s under the non-stimulated condition. We fit the region of interest (ROI) fitting to a single granule and calculated the averages of the fluorescence intensity in the ROI during the exocytosis procedure. The fluorescence intensity at 2 and 5 s after the opening of the secretory granules was divided by the maximum intensity and is shown as a percentage (RR-2s and RR-5s).

**TIRF microscope system**

The optical instrument for visualizing the exocytosis process of tPA-GFP secretory granules consisted of an Olympus inverted microscope (IX81; Olympus Corp., Tokyo, Japan, 60×/1.45 numeric aperture oil-immersion objective) equipped with a TIRF unit for generating an evanescent field which enabled us to excite only the fluorophore present in the immediate vicinity of the plasma membrane; an automatic focus device (ZDC2); a digital complementary metal oxide semiconductor (CMOS) camera (ORCA-Flash4.0, C11440; Hamamatsu Photonics, Hamamatsu, Japan), and a temperature controller to keep the cells at 37 °C on the microscope stage (INUG2-ONID-BE; Tokai Hit, Shizuoka, Japan). tPAs-GFP was excited by a 488-nm laser with a 1.3 neutral density filter (Edmond Optics, Tokyo, Japan), and emissions were collected through a 520/35-nm band pass filter (Semrock, Rochester, NY, USA). HCIMAGE software (Hamamatsu Photonics) was used to capture the fluorescence images. The fluorescence intensity of an ROI in individual secretory granules was measured and analyzed on an Aquacosmos imaging station (Hamamatsu Photonics).
Measurement of clot lysis time, plasmin generation, and GFP concentration

Confluent cells in 96-well plates were used for transfection with plasmids. After the 24-h cultured supernatant was collected, the cells were washed with HBS and supplemented with 0.5 μM plasminogen (purified from fresh-frozen human plasma), 1 U/mL thrombin (Benesis, Osaka, Japan), and 3 μM fibrinogen (Enzyme Research Laboratories, South Bend, IN, USA) to form fibrin clots (final volume 200 μL). The clots were overlaid with liquid paraffin, and the absorbance at 405 nm (A405) of each well was measured every 20 min at 37 °C to monitor the turbidity. The clot lysis time was determined as the time when A405 declined to one-half of its original value.

Plasmin activity on the cell surface was assessed by a chromogenic assay [11]. First, the 24-h cultured supernatant after plasminid transfection to confluent cells in 96-well plates was collected, and then the cells were washed with HBS and supplemented with 1 μM plasminogen and 0.4 mM S-2251 (Chromogenix, Mölndal, Sweden) (final volume 100 μL). The reaction mixture was overlaid with liquid paraffin, and A405 was measured every 10 min at 37 °C. The rate of plasmin generation was determined by the following calculation: A405 [m optical density] divided by the square of the time [h]. The values, normalized to estimate the rate of plasmin generation per 1 ng of GFP (which was calculated based on the GFP concentration in individual supernatants) in the variants are shown as the ratio compared to that in the wild-type.

The concentrations of tPA-GFP in the supernatants obtained after 24 h of incubation from the individual wells described above were determined using the GFP ELISA Kit (ab117992, Abcam, Cambridge UK).

Detection of tPAs-GFP in supernatant by western blotting of GFP

Culture medium was collected after 24 h of incubation from untransfected or transfected cells with tPAs-GFP expression vectors using a 6-well culture plate. Under the nonreduced condition, 15 μL of sample mixed with the sample buffer were separated by 7% SDS/PAGE. Protein bands transferred to a nitrocellulose membrane were incubated with anti-GFP antibody (Molecular Probes, Eugene, OR, USA), and horseradish peroxidase (HRP)-conjugated secondary antibodies. Signals were visualized by enhanced chemiluminescence (ECL) western blotting detector reagents (GE Healthcare, Little Chalfont, UK).

Accumulation of plasminogen on VECs

A trace amount of Alexa Fluor 568-labeled plasminogen (plg-568) with 0.5 μM nonlabeled plasminogen in HBS was supplemented to tPAs-GFP-expressing cells in 35-mm glass-bottom dishes and incubated at 37 °C on the stage of a confocal laser scanning microscope (CLSM; FV1000, Olympus). The accumulation of plg-568 on and around the surface of individual tPAs-GFP-expressing cells was determined as the increase in values in plg-568 fluorescence intensity for 30 min (df30 min; the ratio of fluorescence intensity at 50 min compared to that at 20 min) using the most basal focal images in which the cells were just adhering to the glass.

Statistical analysis

Correlation coefficients between the clot lysis time/the rate of plasmin generation and the amounts of GFP secretion were evaluated with either the Williams multiple comparison test, Student’s t-test (for normal distribution), or Mann–Whitney’s U-test (for non-normal distribution) as needed.

Results

Quantitative evaluation of PA activities

Plots of the GFP concentration values in the supernatant from tPA-GFP-expressing VECs versus the corresponding clot lysis time (CLT) showed a strong negative correlation (Fig. 1A; open circles, \(r = -0.93\), \(P < 0.001\)). The fibrin clots that formed on the cells not expressing tPA-GFP showed very little or no dissolution in the 40-h observation period after clot formation \((n = 5)\), indicating that the activity of endogenous plasminogen activators, that is, tPA as well as urokinase-type plasminogen activator, were not enough to change the fibrin clot turbidity. This inhibition was mainly due to the endogenously expressed PAI-1, because much of the endogenous tPA existed as tPA-PAI-1 complex in the supernatant [2].

The real-time visualization of fibrin clot lysis using labeled plasminogen and fibrinogen showed that lysis started only where tPA-GFP-expressing cells existed [6], suggesting that tPA-GFP secreted from its expressing cells overcome the inhibitory effect of endogenous PAI-1 and expresses its plasminogen activator activity at a local area. Therefore, the clot lysis time strongly correlated with the amounts of secreted tPA-GFP.

Similarly, the plots of GFP versus the surface-associated plasmin generation showed a positive correlation (Fig. 1A, closed circles; \(r = 0.66\), \(P = 0.0014\)). Plasmin generation in cells not expressing tPA-GFP after 1 μM plasminogen supplementation was detected but was...
negligible (1.48 ± 0.42 mOD h⁻² [mean ± SD, n = 5]) even though the cells expressed endogenous plasminogen activators. Plasminogen activation activity, represented as the rate of plasmin generation (RPG)/ng.GFP, normalizing the secretion levels of GFP, was substrate concentration-sensitive and increased dose-dependently with increasing concentrations of supplemented plasminogen (Fig. 1B). Although the dissociation rates of tPA-GFP from the membranous secretory granules after exocytosis were heterogeneous (shown as the retention rate in Fig. 2B, C; open circles), the GFP concentration in the supernatant (mostly tPA-GFP-PAI-1 complex, and a negligibly small amount in free form; Fig. 3, wild-type) seems to correlate well with the amounts and activities of surface-retained tPA-GFP.

**Secretory characteristics of TNK-/K-tPA-GFP**

We visualized the secretory dynamics of wild-type and TNK-/K-tPA-GFP expressed in EA.hy926 cells (Fig. 2A) by using TIRF microscopy. The supplemental movies (Movie S1; wild-type tPA-GFP and S2; K-tPA-GFP) showed more rapid dispersion of exocytosed K-tPA-GFP than that of wild-type tPA-GFP. We determined the retained ratio (RR) of tPAs-GFP on the membrane surface after the secretory granular opening, which reflected the residual amounts of tPAs-GFP on the membrane surface facing the extracellular fluid. The results obtained for TNK-/tPA-GFP and K-tPA-GFP were significantly less than that for wild-type tPA (Fig. 2B, C), indicating that positively charged amino acid sequences, KHRR(296-299) residues are important for the retention of tPA-GFP. In light of our detection of the free forms of TNK-/K-tPA-GFP in 24-h cultured supernatant, which clearly contrasts with the detection of only the complex form with PAI-1 in wild-type tPA-GFP (Fig. 3), the replacement of KHRR to AAAA seems to have altered the charge-dependent interaction with the membrane and facilitated the diffusion of TNK-/K-tPA-GFP from the site of the opened granule into the liquid phase. Our trial to confirm the existence of free TNK-/K-tPA-GFP in the supernatant by western blotting using anti-tPA antibody, however, was not successful due to the fact that the signals derived from the endogenous tPA-PAI-1 complex and the expressed free form of tPAs-GFP were too close and difficult to be distinguished (Data not shown).

**Two differential activities in TNK-/K-tPA-GFP**

We applied our novel quantitative methods to evaluate the activities of tPA variants originated from their unique characteristics. Scatter plots of CLT ver-
sus GFP concentrations in 24-h cultured supernatant from TNK-/K-tPA-GFP-expressing VECs were largely different and distributed at the left and lower side (Fig. 4, TNK: closed triangles, \( r = 0.87, P < 0.001, n = 20 \); and K: open squares, \( r = 0.67, P = 0.005, n = 16 \)) compared to those from wild-type, even though the secretion of TNK-/K-tPA-GFP was lower.

Interestingly, the accumulation of plg-568 at the cell-surface/pericellular area where cells were adhering to the glass was significantly decreased in K-tPA-GFP (decreased tendency in TNK-tPA-GFP; \( P = 0.06 \)) expressing cells compared to that in the wild-type (Fig. 5A,B). This result coincided with the plasminogen activation activity represented as the values of normalized plasmin generation (Fig. 5C), indicating that
plasminogen activation, augmented plasminogen bind-

VEC surface-retained tPA-GFP. In this facilitated
mainly reflects plasminogen activation initiated by
min generation analysed by a chromogenic assay
as a complex form with PAI-1 in EA.hy926 cells, plas-
plasminogen activator activities.

strongly correlated with retained tPA-GFP-triggered
Correlations of these two factors were obtained using Pearson’s
correlation coefficient in wild-type tPA-GFP (open circles,
$r = -0.93, t = -11.20, P < 0.001, n = 21$), in K-tPA-GFP (open
squares, $r = -0.67, t = -3.34, P = 0.005, n = 16$), and in TNK-tPA-
GFP (closed triangles, $r = -0.87, t = -7.49, P < 0.001, n = 20$).

retained tPA was primarily responsible for the increase
in plasmin generation assessed by this method.

Discussion

Vascular endothelial cells, as well as fibrin clots, pro-
vide a solid surface where fibrinolytic components
can assemble and interact with each other for effec-
tive plasminogen activation [5,12]. We previously
demonstrated that the heavy chain of tPA-GFP is
essential for the cell-surface retention by showing that
the heavy-chain-deleted mutant form of tPA-GFP is
not retained on the membrane surface after exocyto-
sis [2]. Since the retention of tPA-GFP on a VEC is
essential for both cell surface-associated plasminogen
activation and effective fibrin clot lysis [6], we
tried to quantify the expressed tPA-GFP-trig-
ered plasminogen activator activities by employing
two different methods to analyze fibrinolysis and
plasminogen activation. Our present findings demon-
strated that the amounts of secreted tPA-GFP
strongly correlated with retained tPA-GFP-triggered
plasminogen activator activities.

Since most of the tPA-GFP in the fluid phase exists
as a complex form with PAI-1 in EA.hy926 cells, plas-
min generation analysed by a chromogenic assay
mainly reflects plasminogen activation initiated by
VEC surface-retained tPA-GFP. In this facilitated
plasminogen activation, augmented plasminogen bind-
ing to VEC surface, shown as plg-568 accumulation in
the previous study [6], is indeed deeply involved in the
newly exposed C-terminal lysine residues by the gener-
ated plasmin-dependent degradation of proteins at the
cell-surface/pericellular area.

According to observations of the secretory dyna-
ics of tPA-GFP by TIRF microscopy, exocytosed
tPA-GFP was retained as fluorescent spots on the
membrane surface without any internalization in
VECs [2], which is different from that in excitable
cells [13,14]. In the present study, the retained fluo-
rescent spots of tPA-GFP were gradually dimming, sug-
gest that tPA-GFP was gradually released. We
thus suspected that this slow release of tPA-GFP
consisted of two factors: one is a diffusion of tPA-
GFP from the site of the opened granule into the liq-
uid phase, and the other is a diffusion of tPA-GFP
into the surrounding plasma membrane (lateral diffu-
sion). Although the latter seems more important for
the expression of its enzymatic activity, we have not
identified the binding molecule of tPA-GFP on the
cell surface, despite our efforts to assess the possible
binding to reported tPA receptors [15] such as
annexin A2 and galectin 1 (Y. Suzuki, unpubl. data).
The fluorescence of tPA-GFP diffused into the
plasma membrane—as well as that on the fibrin clot
lysic edge where a large amount of labeled plasmino-
gen accumulated—was less than the detection limit
and was hardly visualized [6], but the amount was
enough to express plasminogen activator activity. In
any case, the GFP concentration in the supernatant,
which correlates with the plasminogen activator activ-
ity triggered by secreted tPA-GFP, might be useful as
a substitute for the active form of tPA-GFP. Further,
measuring the GFP concentration instead of the tPA
concentration to determine the amounts of tPA-GFP
is more practical for assessing variant tPA-GFP
concentrations, since anti-tPA antibody may react differ-
ently with different kinds of variant tPA.

Since PAI-1 dissociates retained tPA from the VEC
surface by forming high molecular weight complexes
[2], we expected TNK/K-tPA-GFP to be retained
longer due to its impaired charge-dependent interac-
tion with PAI-1 through its negatively charged residues
‘EEIIMD (350–355)’ [16]. Contrary to our expecta-
tions, TNK/K-tPA-GFP dissociated faster than
wild-type tPA-GFP after its secretory granular open-
ing. Our present findings demonstrated for the first
time that tPA interacts with the plasma membrane sur-
face in a charge-dependent manner. Further studies
are needed to clarify which negatively charged factor is
responsible for tPA interactions on the membrane
surface.
The reduced binding affinity of TNK/K-tPA-GFP toward the membrane developed interesting results in the present novel quantitative methods. In addition to their important characteristics of both higher resistance to PAI-1 and higher affinity to fibrin clot [17,18], faster release from VEC surface as a free tPA seems to have also contributed to the more effective fibrin clot lysis. These newly identified characteristics in the present study also contributed toward the less-effective plasmin generation on the surface of VEC. Thus, the characteristics of tenecteplase having lower affinity to the plasma membrane compared to alteplase might be beneficial as a thrombolytic agent due to the following two reasons. First, higher effective drug concentration in the circulating blood could be expected after intravenous infusion. Second, tPA-mediated deleterious effects on neurovascular units in the ischemic brain [19], which were partially evoked by the overexpression of VEC surface-associated plasmin activity [20,21], could be reduced.

In conclusion, the combination of our novel quantitative methods demonstrated that fibrinolysis and plasmin generation on VECs are distinctly regulated, and the methods were shown to be useful for evaluations of the function of variant tPA molecules with different characteristics. The elucidation of such activity on the surface of VEC, which seems different from those in a purified system, may contribute to the development of a more beneficial tPA variant, including tenecteplase, in which KHRR residues are modified.

**Acknowledgements**

This work was supported by Grants-in-Aid for Scientific Research (C: 25461123) to YS and (C: 24590273) to TU from the Japan Society for the Promotion of Science (JSPS), grants from the Naito Foundation, the Takeda Science Foundation, and SENSIN Medical Research Foundation to YS, and a grant from the Smoking Research Foundation to TU.
**Author contributions**

YS designed the study, performed experiments, and wrote the manuscript. HS analyzed and interpreted the data. MT and TB made manuscript revisions. TU supervised the study and wrote the manuscript.

**References**

1. Kruithof EK and Dunoyer-Geindre S (2014) Human tissue-type plasminogen activator. *Thromb Haemost* **112**, 243–254.

2. Suzuki Y, Mogami H, Ihara H and Urano T (2009) Unique secretory dynamics of tissue plasminogen activator and its modulation by plasminogen activator inhibitor-1 in vascular endothelial cells. *Blood* **113**, 470–478.

3. Weiss AN, Bittner MA, Holz RW and Axelrod D (2014) Protein mobility within secretory granules. *Biophys J* **107**, 16–25.

4. Weiss AN, Anantharam A, Bittner MA, Axelrod D and Holz RW (2014) Luminal protein within secretory granules affects fusion pore expansion. *Biophys J* **107**, 26–33.

5. Rijken DC and Lijnen HR (2009) New insights into the molecular mechanisms of the fibrinolytic system. *J Thromb Haemost* **7**, 4–13.

6. Suzuki Y, Yasui H, Brzoska T, Mogami H and Urano T (2011) Surface-retained tPA is essential for effective fibrinolysis on vascular endothelial cells. *Blood* **118**, 3182–3185.

7. Parsons M, Spratt N, Bivard A, Campbell B, Chung K, Miteff F, O’Brien B, Bladin C, McElduff P, Allen C, et al. (2012) A randomized trial of tenecteplase versus alteplase for acute ischemic stroke. *N Engl J Med* **366**, 1099–1107.

8. Coutts SB, Dubuc V, Mandzia J, Kenney C, Demchuk AM, Smith EE, Subramaniam S, Goyal M, Patil S, Menon BK, et al. (2015) Tenecteplase–tissue-type plasminogen activator evaluation for minor ischemic stroke with proven occlusion. *Stroke* **46**, 769–774.

9. Edgell CJ, McDonald CC and Graham JB (1983) Permanent cell line expressing human factor VIII-related antigen established by hybridization. *Proc Natl Acad Sci USA* **80**, 734–737.

10. Emeis JJ and Edgell CJ (1988) Fibrinolytic properties of a human endothelial hybrid cell line (Ea.hy 926). *Blood* **71**, 669–675.

11. Chibber BA, Morris JP and Castellino FJ (1985) Effects of human fibrinogen and its cleavage products on activation of human plasminogen by streptokinase. *Biochemistry* **24**, 3429–3434.

12. Kolev K and Machovich R (2003) Molecular and cellular modulation of fibrinolysis. *Thromb Haemost* **89**, 610–621.

13. Taraska JW and Almers W (2004) Bilayers merge even when exocytosis is transient. *Proc Natl Acad Sci USA* **101**, 8780–8785.

14. Tsuboi T, McMahon HT and Rutter GA (2004) Mechanisms of dense core vesicle recapture following “kiss and run” (“cavicapture”) exocytosis in insulin-secreting cells. *J Biol Chem* **279**, 47115–47124.

15. Roda O, Chiva C, Espuna G, Gabius HJ, Real FX, Navarro P and Andreu D (2006) A proteomic approach to the identification of new tPA receptors in pancreatic cancer cells. *Proteomics* **6** (Suppl 1), S36–S41.

16. Ibarra CA, Blouse GE, Christian TD and Shore JD (2004) The contribution of the exosite residues of plasminogen activator inhibitor-1 to proteinase inhibition. *J Biol Chem* **279**, 3643–3650.

17. Keyt BA, Paoni NF, Refino CJ, Berleau L, Nguyen H, Chow A, Lai JA, Pena L, Pater C, Ogez J, et al. (1994) A faster-acting and more potent form of tissue plasminogen activator. *Proc Natl Acad Sci USA* **91**, 3670–3674.

18. Stewart RJ, Fredenburgh JC, Leslie BA, Keyt BA, Rischké JA and Weitz JI (2000) Identification of the mechanism responsible for the increased fibrin specificity of TNK-tissue plasminogen activator relative to tissue plasminogen activator. *J Biol Chem* **275**, 10112–10120.

19. Yepes M, Roussel BD, Ali C and Vivien D (2009) Tissue-type plasminogen activator in the ischemic brain: more than a thrombolytic. *Trends Neurosci* **32**, 48–55.

20. Niego B, Freeman R, Puschmann TB, Turnley AM and Medcalf RL (2012) t-PA-specific modulation of a human blood-brain barrier model involves plasmin-mediated activation of the Rho kinase pathway in astrocytes. *Blood* **119**, 4752–4761.

21. Niego B and Medcalf RL (2014) Plasmin-dependent modulation of the blood-brain barrier: a major consideration during tPA-induced thrombolysis? *J Cereb Blood Flow Metab* **34**, 1283–1296.

**Supporting information**

Additional Supporting Information may be found online in the supporting information tab for this article:

**Movie S1.** Secretory dynamics of wild-type tPA-GFP in EA.hy926. Movie depicting secretory dynamics at partial area indicated as white box in Fig. 2A is shown. Images were acquired at 3.2 frames per s.

**Movie S2.** Secretory dynamics of K-tPA-GFP in EA.hy926. Movie depicting secretory dynamics at partial area indicated as white box in Fig. 2A is shown. Images were acquired at 3.2 frames per s.